SCHEMBL6712962

SCHEMBL6712962

Oc1ccc(C=NNc2nccnc2Cl)c(O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 10/20 1.00
KMT2A Q03164 10/20 1.00
MEN1 O00255 9/20 1.00
PKM P14618 8/20 1.00
MAPT P10636 8/20 1.00
SMN1; SMN2 Q16637 5/20 1.00
KDM4E B2RXH2 5/20 1.00
LMNA P02545 4/20 1.00
ALDH1A1 P00352 4/20 1.00
HPGD P15428 3/20 1.00
HTT P42858 5/20 0.71
POLB P06746 5/20 0.71
RAB9A P51151 10/20 0.66
NPC1 O15118 8/20 0.66
NCOA1 Q15788 1/20 0.58
NCOA3 Q9Y6Q9 1/20 0.58
TDP1 Q9NUW8 5/20 0.56
MCL1 Q07820 1/20 0.56
L3MBTL1 Q9Y468 5/20 0.54
HKDC1 Q2TB90 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715893 0.83 SMN1; SMN2 (1.00) GAAKMT2AMEN1PKMMAPT
SCHEMBL7961929 0.80 KMT2A (0.67) GAAKMT2AMEN1PKMMAPT
SCHEMBL7961926 0.80 KMT2A (0.67) GAAKMT2AMEN1PKMMAPT
SCHEMBL13779312 0.73 NCOA1 (1.00) GAAKMT2AMEN1PKMMAPT
SCHEMBL1132558 0.71 MEN1 (0.58) GAAKMT2AMEN1PKMMAPT
SCHEMBL1132559 0.71 MEN1 (0.58) GAAKMT2AMEN1PKMMAPT
SCHEMBL7963156 0.71 GAA (0.57) GAAKMT2AMEN1PKMMAPT
SCHEMBL7963150 0.71 GAA (0.57) GAAKMT2AMEN1PKMMAPT
SCHEMBL1132551 0.70 MEN1 (0.64) GAAKMT2AMEN1PKMMAPT
SCHEMBL1132181 0.70 MEN1 (0.64) GAAKMT2AMEN1PKMMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US claimed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US claimed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US claimed
US-20040053977-A1 Medicinal uses of hydrazones ALMSTEAD JI-IN KIM (US) 2004-03-18 US disclosed
US-6660737-B2 Antihypoxic agents THE PROCTER & GAMBLE COMPANY 2003-12-09 US disclosed
US-20030092716-A1 Medicinal uses of hydrazones THE PROCTER & GAMBLE COMPANY 2003-05-15 US disclosed
WO-2002089809-A1 MEDICINAL USES OF HYDRAZONES AND HYDRAZINES THE PROCTER & GAMBLE COMPANY (US) 2002-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040053977-A1 Medicinal uses of hydrazones PGF, VEGFA, TEK GAA 1089/4885KMT2A 3683/4885MEN1 1753/4885
US-20030092716-A1 Medicinal uses of hydrazones EPOR, VEGFA, HIF1A GAA 635/4885KMT2A 4156/4885MEN1 1904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.